Premium
Extravasation reactions associated with the administration of pamidronate: 11 cases (2008–2013)
Author(s) -
Marker B. A.,
Barber L. G.,
Clifford C. A.,
Correa S. S.,
Thalhofer P. L.,
LaDue T. A.,
Mullin C. M.,
Sauerbrey M. L.,
Wood C. C.
Publication year - 2017
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12191
Subject(s) - extravasation , medicine , osteolysis , complication , drug reaction , surgery , bisphosphonate , pathology , drug , osteoporosis , psychiatry
Pamidronate is a bisphosphonate drug widely utilized in veterinary oncologic practice for the palliation of malignant osteolysis. Pamidronate has not been previously reported to cause tissue injury upon extravasation in dogs. The medical records of 11 client‐owned dogs undergoing palliative treatment for primary bone tumors with known or suspected pamidronate extravasation reactions were reviewed. The majority of adverse events were low grade in nature, however in some cases, the reactions were severe and led to euthanasia in one instance. Time to complete resolution of lesions ranged from within several days to greater than one and a half months. Aside from the dog that was euthanized, no long‐term sequelae of extravasation were identified. Treatments employed to address the reactions varied widely. Pamidronate extravasation reaction appears to be an uncommon, but potentially serious complication of intravenous administration.